Novo Integrated Sciences Granted Natural Product Number (NPN) by Health Canada for IoNovo Iodine Branded Product
Novo Integrated Sciences (NASDAQ:NVOS) announced that its subsidiary, Novo Healthnet Limited, received a Natural Product Number (NPN) from Health Canada for its IoNovo Iodine. This proprietary iodine micronutrient is delivered in an oral or nasal spray form, promoting high bioavailability. The product supports personal biosecurity and is recognized for its disinfectant properties. The recent acquisition of Terragenx Inc. enables its immediate commercialization. Novo emphasizes a holistic healthcare approach through integrated technology and multidisciplinary services.
- Granting of Natural Product Number (NPN) for IoNovo Iodine by Health Canada enhances product credibility.
- Recent acquisition of Terragenx Inc. allows immediate market entry for IoNovo Iodine.
- IoNovo Iodine offers a 100% natural and safe alternative for health solutions.
- None.
Novo’s recent acquisition of
IoNovo Iodine oral spray is
About
We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.
The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:
- First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.
- Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.
- Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.
Innovation through science combined with the integration of sophisticated, secure technology assures
For more information concerning
Twitter, LinkedIn, Facebook, Instagram, YouTube
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," “intend,” "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in Novo’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005093/en/
chris.david@novointegrated.com
(888) 512-1195
Source:
FAQ
What is the significance of the NPN granted to Novo Integrated Sciences for IoNovo Iodine?
When was the NPN for IoNovo Iodine announced?
What benefits does IoNovo Iodine provide?
How does Novo Integrated Sciences plan to market IoNovo Iodine?